GlassScriptPhysician profile
Rohini Bajaj
NPI 1235245804
$1,693.09
in general payments reported to CMS, 2019-2025
19 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $37.93 · 2021: $27.70 · 2022: $20.22 · 2023: $225 · 2024: $638 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.66 | 2023-2025 | Relistor, Xifaxan, Plenvu |
| Abbvie INC. | $368.12 | 2023-2025 | Viberzi, Linzess |
| Bard Peripheral Vascular, INC. | $112.22 | 2019-2021 | |
| Janssen Biotech, INC. | $107.84 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Amgen INC. | $103.24 | 2019 | |
| Ardelyx, INC. | $92.32 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $88.82 | 2023-2025 | Voquezna |
| Braintree Laboratories, INC. | $67.96 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $55.80 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $47.31 | 2024 | Dificid |
| Olympus America INC. | $44.49 | 2019-2025 | Endoclot Phs |
| Ferring Pharmaceuticals INC. | $35.85 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $34.08 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $24.25 | 2019 | |
| Celltrion USA INC. | $23.22 | 2025 | Vegzelma |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $21.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.22 | 2022 | |
| Axonics, INC. | $18.85 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $16.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohini Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.